Alzamend Neuro (NASDAQ:ALZN) Releases Quarterly Earnings Results, Beats Expectations By $0.10 EPS

Alzamend Neuro (NASDAQ:ALZN) posted its quarterly earnings data on Monday. The company reported ($0.19) earnings per share for the quarter, topping the consensus estimate of ($0.29) by $0.10, Zacks reports.

Alzamend Neuro Stock Down 6.8 %

Shares of NASDAQ ALZN traded down $0.05 during mid-day trading on Monday, reaching $0.71. 92,032 shares of the company’s stock traded hands, compared to its average volume of 556,061. Alzamend Neuro has a 1-year low of $0.69 and a 1-year high of $15.06. The business has a 50-day simple moving average of $1.07 and a 200 day simple moving average of $1.44.

Analysts Set New Price Targets

Separately, Ascendiant Capital Markets cut their target price on shares of Alzamend Neuro from $35.00 to $32.00 and set a “buy” rating on the stock in a research note on Monday, December 16th.

Alzamend Neuro Company Profile

Alzamend Neuro, Inc, an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease.